Newamsterdam pharma announces commencement of $300 million public offering of ordinary shares and pre-funded warrants

Naarden, the netherlands and miami, dec. 10, 2024 (globe newswire) -- newamsterdam pharma company n.v. (nasdaq: nams; “newamsterdam” or the “company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“cvd”) with elevated low-density lipoprotein cholesterol (“ldl-c”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of $300.0 million of the company's ordinary shares, nominal value €0.12 per share (the “ordinary shares”), and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares (“pre-funded warrants,” and such offering, the “offering”). all ordinary shares and pre-funded warrants to be sold in the proposed offering will be sold by the company. in addition, the company expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of ordinary shares, less underwriting discounts and commissions. the proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
NAMS Ratings Summary
NAMS Quant Ranking